ProfileGDS5678 / 1449224_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 48% 42% 42% 39% 42% 41% 40% 41% 42% 42% 41% 37% 41% 42% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1860648
GSM967853U87-EV human glioblastoma xenograft - Control 22.9641542
GSM967854U87-EV human glioblastoma xenograft - Control 32.9658442
GSM967855U87-EV human glioblastoma xenograft - Control 42.8308539
GSM967856U87-EV human glioblastoma xenograft - Control 52.9115842
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0384141
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9782440
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9440441
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9472142
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9621242
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9467741
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.805237
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9589141
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9541442